Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Focal Adhesion Kinase (FAK) Inhibitor Pipeline Insight Report, 2018 - ResearchAndMarkets.com

Research and Markets
Posted on: 03 Dec 18

The "Focal Adhesion Kinase (FAK) Inhibitor -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Focal Adhesion Kinase (FAK) Inhibitor - Pipeline Insight, 2018' reportoffers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Focal Adhesion Kinase (FAK) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Focal Adhesion Kinase (FAK) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the report:

  • Provides a snapshot of the therapeutics pipeline activity for Focal Adhesion Kinase (FAK) Inhibitor
  • Features the Focal Adhesion Kinase (FAK) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Focal Adhesion Kinase (FAK) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Focal Adhesion Kinase (FAK) Inhibitor

Key Topics Covered:

1. Report Introduction

2. Focal Adhesion Kinase (FAK) Inhibitor - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Focal Adhesion Kinase (FAK) Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Focal Adhesion Kinase (FAK) Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Asana BioSciences, LLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wb2ns6/focal_adhesion?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005352/en/

Business Wire
www.businesswire.com

Last updated on: 03/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.